Previous Pause Next
Home >> News Center >>
Investment & Financials
Glaxo Joins J&J in $200 Million Fund With Index Ventures PDF Print E-mail
Thursday, 22 March 2012 07:21

GlaxoSmithKline Plc (GSK) and Johnson & Johnson (JNJ) are forming a $200 million fund with Index Ventures to invest in early-stage biotechnology companies, a move that may entice venture capitalists back to the industry.

Russian Tech Fund Joins U.S. VC Firm in $760M Biopharma Venture PDF Print E-mail
Wednesday, 07 March 2012 14:54

    Russia’s $10 billion state-owned technology fund is joining with a U.S. venture capital firm to put $760 million into U.S. pharmaceutical, diagnostics, and medical device companies as well as create a manufacturing plant and increase drug development in Russia. The Russian Corporation of Nanotechnologies (Rusnano), created to finance nanotech and other high-tech companies, will join with Domain Associates to invest $330 million each, most of which will be used for about 20 companies.

Rempex Pharmaceuticals, Inc. Snags $67.5 Million PDF Print E-mail
Thursday, 10 November 2011 06:16
SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it has completed the initial closing of a Series B financing. New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners in committing to a total of $67.5 million for this round. This financing, together with a previous Series A round, brings the total financing commitment for Rempex to $76 million since the company's founding in June 2011.
Karyopharm Therapeutics Raises $10 Million More in Series A Round PDF Print E-mail
Thursday, 03 November 2011 07:00, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export(SINE) for various cancers. The Company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.
Roche, Forbion Invest in MDx Firm Curetis PDF Print E-mail
User Rating :  / 1
Thursday, 27 October 2011 05:44
Curetis today announced its Series A financing round has increased by €9.6 million ($13.3 million) bringing the total amount raised in the round to €34.1 million.

Roche Venture Fund and Dutch venture capital firm Forbion Capital Partners led the round. CD-Venture and Curetis' management were also participants.

Dermira Scores $42 Million Series A Financing to Fund Therapeutic Advances in Dermatology PDF Print E-mail
Sunday, 23 October 2011 00:58
REDWOOD CITY, Calif., Oct 20, 2011 (BUSINESS WIRE) -- Dermira today announced a $42 million Series A financing to support the acquisition, development and commercialization of novel therapeutics in dermatology. The company was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams, including Tom Wiggans, who will serve as Chief Executive Officer, and Dr. Eugene Bauer, who will serve as Chief Medical Officer, together with Bay City Capital. They are joined by Chris Griffith, previously at Gilead and Bay City Capital, who will serve as the Vice President of Corporate Development and Strategy, and Luis Pena, previously at Stiefel, a GSK Company, who will serve as the Vice President of Product Development.
Merck & Co., Inc. (MRK) Ditches Bone Drug Deal with Japan Tobacco, Inc. PDF Print E-mail
Thursday, 20 October 2011 00:29
Merck & Co has ended a licensing agreement with Japan Tobacco to develop and market an experimental agent that stimulates bone growth for the treatment of osteoporosis, which the Japanese company said it would now drop from development.
Functional Neuromodulation Inc. Closes $10.4 Million Financing Agreements to Fund Phase II Testing for Potential Alzheimer's Treatment PDF Print E-mail
Wednesday, 19 October 2011 00:16
Functional Neuromodulation Inc, a company advancing deep brain stimulation (DBS) therapies for Alzheimer’s Disease, today announced the closing of $10.4 million in commitments from Genesys Capital and Medtronic, Inc. in its latest round of financing.
Roche Buys Anadys Pharmaceuticals, Inc. (ANDS) for $230 Million to Boost Hepatitis Ops PDF Print E-mail
User Rating :  / 1
Wednesday, 19 October 2011 00:10
Anadys Pharmaceuticals, Inc. /quotes/zigman/92552/quotes/nls/ands ANDS +251.92% today announced that it has entered into a definitive merger agreement to be acquired by Roche (six:RO)(six:ROG)(otcqx:RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share.
Forest Labs looks longterm for next product deals PDF Print E-mail
Tuesday, 18 October 2011 00:54

Forest Laboratories Inc (FRX.N) is looking more at earlier-stage products to acquire rather than more advanced ones because it feels confident it can weather the patent expirations of its two biggest medicines, the drugmaker's finance chief said on Thursday.

Opinion: A Big Pharma Biotech Fund PDF Print E-mail
User Rating :  / 1
Wednesday, 07 March 2012 15:17

Pharmaceutical companies should deploy cash to fund struggling biotech companies, which could generate much needed new drugs.

The biotech industry, one of the US economy’s most innovative sectors, continues to confront massive challenges in raising vital capital for growth.  In addition to threatening the United States’ historical leadership in this area, this mounting problem has important near- and long-term implications for big pharmaceutical companies with pinched R&D budgets struggling to create new drugs, the country’s job growth, and the world’s overall well-being.  However, an effective solution can be devised by creating a Biotech Fund that smartly deploys Big Pharma’s cash to solve the capital crunch of this critical sector of our economy.

Aragon Pharmaceuticals, Inc. Nabs $42 Million, Targets Hormone-Driven Cancers PDF Print E-mail
Wednesday, 07 March 2012 06:42 DIEGO, March 6, 2012 - Aragon Pharmaceuticals today announced that the company has secured $42 million in an oversubscribed Series C financing to advance Aragon's pipeline of therapies targeting hormone-driven cancers, including ARN-509, the company's lead compound for the treatment of castration-resistant prostate cancer (CRPC).
Clovis Oncology Poised for IPO, Targets $13 to $15 Per Share PDF Print E-mail
Thursday, 03 November 2011 07:07 Oncology Inc., a biotech drug research company, has priced its shares at between $13 and $15 for an initial public offering that could take place any day.

The Boulder-based startup filed a prospectus stating the price range for 9.3 million shares it plans to sell.

Selecta Biosciences, Inc. Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies PDF Print E-mail
Friday, 28 October 2011 06:19
WATERTOWN, Mass.--(BUSINESS WIRE)-- Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that it has secured new funding from RUSNANO, existing investors, and additional new investors. RUSNANO, a $10-billion Russian Federation fund that supports nanotechnology advances, entered as a significant new investor in Selecta in this new $47.25 million financing which will broaden Selecta’s research and development (R&D) capabilities and advance its new class of vaccines and immunotherapies.
Novartis AG (NVS), Vectura Group plc (VEC.L) Lung Drugs Face Delay; Vectura Falls -20.15 (23.71%) @ 10:06AM EDT PDF Print E-mail
Tuesday, 25 October 2011 06:53

Shares in U.K. drug maker Vectura Group PLC (VEC.LN) fell more than 20% Tuesday after its partner Novartis AG (NOVN.VX) reported delays to the U.S. regulatory approval of key lung drug NVA237. Novartis said U.S. regulators have asked for further clinical data on the drug, an inhaled powder for the treatment of chronic obstructive pulmonary disease, a lung condition known as smoker's lung.

Marina Biotech, Inc. Announces a $15 Million Purchase Agreement With Lincoln Park Capital Fund, LLC PDF Print E-mail
Thursday, 20 October 2011 00:34
Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor, whereby LPC has committed to invest, at the Company's sole option, up to $15 million of equity capital.
Acino Holding Ltd to Buy Cephalon, Inc. Units For EU 80 Million Cash, Shares PDF Print E-mail
Thursday, 20 October 2011 00:26
Acino and Cephalon Inc. has entered into an agreement under which Acino will acquire Cephalon's combined Middle East and African business for a total consideration of approximately 80 million euros.
Sofinnova Ventures Raises $440 Million for Biotech-Only VC Fund PDF Print E-mail
Wednesday, 19 October 2011 00:14
Amid the doom and gloom of venture investing in biotech, Sofinnova Ventures said Monday that it has raised a $440 million life sciences-focused fund.
Epizyme Wins $4 Million Milestone Payments From GlaxoSmithKline (GSK) Deal PDF Print E-mail
Tuesday, 18 October 2011 00:56

Cambridge-based Epizyme Inc. will be getting a $4 million milestone payment from its collaboration partner GlaxoSmithKline (GSK) now that it has reached a certain pre-clinical stage in the development of potential enzyme-based cancer treatments.

Capstone Therapeutics Announces Plan to Preserve Cash During Ongoing Partnering Efforts, Cutting Staff Down to 4 PDF Print E-mail
Tuesday, 18 October 2011 00:42
Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today its plan to preserve cash during ongoing discussions with potential partners regarding AZX100 in dermal scarring. The Company will reduce staff from its current 18 full-time employees to a core of four individuals covering required regulatory and financial functions at substantially reduced compensation.
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 110